v3.26.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Jun. 30, 2026
Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income (loss) $ (963,616) $ (5,057,523)
Adjustments to reconcile net income/loss to net cash flows used in operating activities:    
Amortization of debt discount to interest expense 243,353
Stock based compensation 67,012 125,127
Derivative expense 343,399
Change in fair value of derivative liabilities 2,133,599
Depreciation expense 8,312 12,571
Impairment of intangible assets 13,337
Changes in operating assets and liabilities:    
Inventories (57)
Prepaid expenses (110,478) (48,272)
VAT receivable (25,108)
Accounts payable 50,173 265,012
Accrued liabilities (9,038) 256,758
Net cash used in operating activities (944,298) (1,751,141)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Cash received in acquisition of Phytanix Bio 943,180
Net cash provided by investing activities 943,180
CASH FLOWS FROM FINANCING ACTIVITIES:    
Increase in note payable for acquisition of Phytanix Bio 583,878
Net proceeds from notes payable
Proceeds from sale of common stock 395,474
Proceeds from exercise of warrants 3,949,730
Proceeds from related party loans 77,756
Net cash provided by financing activities 5,006,838
NET INCREASE IN CASH (944,298) 4,198,877
Effect of exchange rate adjustments on cash 1,105 (117,219)
CASH, beginning of period 1,509,178 14,531
CASH, end of period 565,985 4,096,189
SUPPLEMENTAL SCHEDULE OF CASH FLOW INFORMATION:    
Interest paid
Income taxes paid
NON-CASH INVESTING AND FINANCING INFORMATION:    
Net assets acquired of Phytanix Bio, net of cash paid $ 1,399,079